Trastuzumab biosimilar - Biocad

Drug Profile

Trastuzumab biosimilar - Biocad

Alternative Names: BCD-022; HERtiCAD

Latest Information Update: 12 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biocad
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Breast cancer

Most Recent Events

  • 07 Oct 2016 Efficacy and safety data from a phase III trial in Breast cancer presented at the 41st European Society for Medical Oncology Congress (ESMO - 2016)
  • 01 Oct 2016 Biocad completes a phase III trial in Breast cancer (Combination therapy, First-line therapy, Metastatic disease) in Russia, India, Ukraine and Belarus (IV) (NCT01764022)
  • 20 Jan 2016 Registered for Breast cancer (Combination therapy, First-line therapy, Metastatic disease) in Sri Lanka (IV) after January 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top